Ideaya sees clear path to FDA as Servier-partnered eye cancer drug hits goal in phase 2/3 trial
Ideaya sees clear path to FDA as Servier-partnered eye cancer drug hits goal in phase 2/3 trial
Body unavailable. Use the original source.
Ideaya sees clear path to FDA as Servier-partnered eye cancer drug hits goal in phase 2/3 trial
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.